PAG
ALLO icon

Private Advisor Group’s Allogene Therapeutics ALLO Stock Holding History

Private Advisor Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,087
Closed -$33.8K – 2282
2024
Q3 		$33.8K Buy
+12,087
New +$32.2K ﹤0.01% 2360

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Private Advisor Group's ALLO Position: Q4 2024 in Review

Private Advisor Group sold out of Allogene Therapeutics (ALLO) in Q4 2024, closing a stake of 12,087 shares — an estimated $33.8K sold.

Private Advisor Group first reported a position in ALLO in Q3 2024 and held it in 1 quarter. The position peaked at $33.8K in Q3 2024. 174 funds tracked by Wall St. Rank hold ALLO as of Q4 2024.

  • Private Advisor Group reported no remaining Allogene Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Private Advisor Group sold 12,087 Allogene Therapeutics shares in Q4 2024, an estimated $33.8K.
  • Private Advisor Group first reported a position in Allogene Therapeutics in Q3 2024 and held it in 1 quarter.
  • Private Advisor Group's Allogene Therapeutics position peaked at $33.8K in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2024.

Based on Private Advisor Group's 13F filing for Q4 2024, filed 3 Feb 2025.